Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure.Weimin Li, Robert L. Ferris, Sophie Wildsmith et al.|Journal of Clinical Oncology|2020Cited by 27
Relationship between PD-L1 expression and survival in head and neck squamous cell carcinoma (HNSCC) patients (pts)Michael E. Stokes, Norah J. Shire, Sophie Wildsmith et al.|Annals of Oncology|2017Cited by 6
Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the “MOZART” prospective observational studyFrancesco Schettini, Daniele Generali, Manuela Milani et al.|The Oncologist|2024Cited by 6
Next-Generation Sequencing-Based Evaluation of the Actionable Mutational Landscape in Solid Tumors: the “MOZART” Prospective Observational StudyFrancesco Schettini, Daniele Generali, Marianna Sirico et al.|Research Square|2024Cited by 0